If you're wondering how much weight comes back after you stop Wegovy or Zepbound, the trial answer is: much of it, often within a year. In the randomized withdrawal trials, people switched to placebo gained 6.9% over 48 weeks in the STEP 4 trial in JAMA and 14.0% over 52 weeks in the SURMOUNT-4 trial in JAMA, while people who stayed on the drug lost a further 7.9% and 5.5%. The STEP 1 extension study found people regained 11.6 percentage points a year after stopping semaglutide. These are averages across groups in trials, not a forecast for one person.
Disclosure: Before you read on, this page contains affiliate links. Buying through them may earn us a commission.

What the trials found
Two of these trials randomly assigned people to keep the drug or switch to placebo. The STEP 1 extension followed people after they stopped, and its authors called that part exploratory.
Quick facts, dated 2026-11-19
| Measure | Result | Source and year |
|---|---|---|
| STEP 4, semaglutide 2.4 mg | Placebo +6.9%; continued semaglutide -7.9%, over 48 weeks | JAMA, 2021 |
| SURMOUNT-4, tirzepatide | Placebo +14.0%; continued tirzepatide -5.5%, over 52 weeks | JAMA, 2024 |
| STEP 1 extension, semaglutide stopped | Regained 11.6 percentage points by a year after stopping | Diabetes, Obesity and Metabolism, 2022 |
| Cleveland Clinic records study, surgery | About 28% two-year weight loss in the press release; 26.6% in the conference abstract | Cleveland Clinic release and Healio, November 2026 |
| Cleveland Clinic records study, stopping | 4% two-year weight loss, per Healthline | Healthline, November 2026 |
The three trials side by side
| Trial | Drug and dose | People | Weeks | Result | Journal and year |
|---|---|---|---|---|---|
| STEP 4 | Semaglutide 2.4 mg weekly, continued or switched to placebo | 803 adults randomized (535 continued, 268 placebo) after a 20-week run-in | 48 | Placebo +6.9%; continued semaglutide -7.9% | JAMA, 2021 |
| SURMOUNT-4 | Tirzepatide, continued or switched to placebo | 670 adults randomized (335 per group) after a 36-week open-label lead-in | 52 | Placebo +14.0%; tirzepatide -5.5% | JAMA, 2024 |
| STEP 1 extension | Semaglutide 2.4 mg, then stopped | 327 participants (semaglutide and placebo groups) followed for a year after treatment ended, from the STEP 1 trial of 1,961 adults without diabetes | About 52 weeks off the drug (to week 120) | Regained 11.6 points vs 1.9 on placebo | Diabetes, Obesity and Metabolism, 2022 |
In the STEP 4 trial, adults had lost 10.6% on average during a 20-week run-in on semaglutide. Then they were randomly assigned to keep taking it or switch to placebo for 48 weeks. The placebo group gained 6.9%, while the semaglutide group lost a further 7.9%, a gap of 14.8 percentage points. Gastrointestinal side effects were also more common on the drug: 49.1% vs 26.1%.
In SURMOUNT-4, people lost 20.9% on average on tirzepatide during a 36-week lead-in. Those switched to placebo gained back 14.0% over the next 52 weeks, while those who continued lost 5.5% more. Of the people who kept taking tirzepatide, 89.5% kept at least 80% of their lead-in loss, compared with 16.6% on placebo.
The STEP 1 extension followed 327 people for a year after treatment ended in the original trial. By week 120, those who had been on semaglutide 2.4 mg had regained 11.6 percentage points, compared with 1.9 for those who had been on placebo. The authors said participants regained two-thirds of their prior loss, and the net loss from week 0 to 120 was 5.6% on semaglutide vs 0.1% on placebo.
The newer real-world picture: a Cleveland Clinic records study
Cleveland Clinic researchers published a study in eClinicalMedicine, and the hospital's press release went out November 14, 2026. This is an observational study. It used health records from 20,486 adults with obesity or type 2 diabetes who had been on semaglutide or tirzepatide, and it compared five paths over two years. Healthline's November 19 report gives these two-year average weight losses:
| Path after first treatment | Healthline's two-year figure (% of body weight, kg) | Conference abstract, per Healio |
|---|---|---|
| Bariatric surgery | 28.2% (about 31.5 kg) | 26.6% |
| Switching between semaglutide and tirzepatide | 16% (about 18 kg) | 16% |
| Continuing the first GLP-1 | 10.9% (12.3 kg) | 10.9% |
| Switching to another weight-loss drug | 8.2% (9.2 kg) | 8.1% |
| Stopping treatment | 4% (4.5 kg) | 3.9% |
The Cleveland Clinic press release puts surgery at about 28%. The Healio conference report gives 26.6% from the ObesityWeek abstract it covers, so the surgery figure differs a little depending on which version you read.
The stopping group lost the least weight. Healthline also reports that one-year HbA1c, a blood sugar measure, dropped 0.48% in the stopping group, compared with 1.32% for those who continued the first drug. Cleveland Clinic's Dr. Aminian, who directs its Bariatric and Metabolic Institute, said in the release that “patients who stopped all treatment had the least weight loss and the smallest metabolic benefits.”
Records studies can show which paths go with which results, but they can't show which path caused the result, because the people on each path differ.
Why weight comes back, as far as the evidence goes
The trials show the pattern, not the cause. Healthline quotes Mir Ali, MD, medical director of the MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center, who was not involved in the study. He calls post-treatment hunger “a biological response, not a personal failure.” That is his view, not a finding of the Cleveland Clinic study. For more on how appetite works, see weight loss and appetite control.
What these studies did not test
As the release and the conference report describe it, the Cleveland Clinic study did not test protein, exercise, dietitian support or any “off-ramp” plan. Those ideas are one expert's advice, which Healthline reports from Mir Ali, who urges having a “concrete ‘off-ramp' plan in place with your doctor.” The 2025 joint nutrition advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society lists nutrition after stopping as an area needing more research. For the protein research itself, see protein and weight loss research. A ClinicalTrials.gov registration NCT06273163 lists a study of strategies to curtail regain after GLP-1 treatment, and its status is terminated.
Who this applies to, and who it doesn't
The STEP 4 and STEP 1 extension trials used semaglutide 2.4 mg weekly, and SURMOUNT-4 used tirzepatide. The trials tested those drugs in trial volunteers, not every drug or dose. The Cleveland Clinic group included adults with type 2 diabetes, with 65.7% of the group having it, per Healio.
If you take Ozempic, its Ozempic FDA label record lists glycemic control in adults with type 2 diabetes, plus heart and kidney uses. Its label is written for a different use than the weight-reduction indication of Wegovy and Zepbound.
Safety: what the labels and trials show
The Wegovy FDA label, revised February 2026, carries a boxed warning for thyroid C-cell tumors and says Wegovy is contraindicated with a personal or family history of MTC or MEN 2. The Zepbound FDA label record has the same boxed warning, and both labels list warnings for acute pancreatitis and acute gallbladder disease.
| Risk | What the evidence shows | Source and year |
|---|---|---|
| Gastrointestinal side effects | 49.1% on continued semaglutide vs 26.1% on placebo | STEP 4, JAMA, 2021 |
| Thyroid C-cell tumors | Boxed warning on the Wegovy and Zepbound labels | FDA labels |
| Pancreatitis and gallbladder disease | Warnings on the Wegovy and Zepbound labels | FDA labels |
The benefit and the trade-off come together. In the trials, the people who stayed on the drug kept most of their loss, and the people who stopped regained much of it.
Common mix-ups
- Trial averages vs your scale. A group average is not your number. Your own weight history is what your prescriber will use.
- Wegovy vs Ozempic. These have different labels, and the STEP trials used semaglutide 2.4 mg.
- Stopping is not the same as no loss. The Cleveland stopping group still averaged a 4% loss over two years, but less than the other paths.
- Trials vs records studies. The trials assigned people by chance. The Cleveland study looked back at records. For how to read claims like these, see weight-management study claims.
Questions to bring to your prescriber
- Given my weight history, what would a change in my plan look like, and when would we talk about it?
- If I stop, what would you monitor, such as blood sugar and blood pressure?
- Which side effects would make a change worth discussing?
- If my coverage or cost changes, what are my options?
- Can a dietitian help me plan protein and strength training?
Whether to continue, change or stop is a decision you make with your prescriber.
Next step: take these questions to your prescriber, and read the GLP-1 questions before starting: safety guide before any decision about your medicine.
By the New Life Wellness Guide Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.